Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Serrano Del Pozo E"'
Autor:
González-Larreategui, Í., Vera, L., Giuntini, F., Martínez-Martín, S., Grueso, J., López, S., Serrano del Pozo, E., Thabussot, H., Macaya, I., Beaulieu, M.E., Vicent, S., Casacuberta-Serra, S., Soucek, L.
Publikováno v:
In European Journal of Cancer October 2022 174 Supplement 1:S47-S47
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Zacarías-Fluck MF; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; lsoucek@vhio.net mzacarias@vhio.net., Massó-Vallés D; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain., Giuntini F; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., González-Larreategui Í; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Department of Cellular Biology, Phisiology, and Immunology, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallés, Spain., Kaur J; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Casacuberta-Serra S; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain., Jauset T; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain., Martínez-Martín S; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain., Martín-Fernández G; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain., Serrano Del Pozo E; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Foradada L; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain., Grueso J; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain., Nonell L; Bioinformatics Unit, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain., Beaulieu ME; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain., Whitfield JR; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Soucek L; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; lsoucek@vhio.net mzacarias@vhio.net.; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), 08035 Barcelona, Spain.
Publikováno v:
Genes & development [Genes Dev] 2023 Apr 01; Vol. 37 (7-8), pp. 303-320. Date of Electronic Publication: 2023 Apr 06.
Autor:
Zacarías-Fluck MF; Mouse Models of Cancer Therapy Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Jauset T; Mouse Models of Cancer Therapy Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Martínez-Martín S; Mouse Models of Cancer Therapy Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Kaur J; Mouse Models of Cancer Therapy Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Casacuberta-Serra S; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Massó-Vallés D; Mouse Models of Cancer Therapy Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Serrano Del Pozo E; Mouse Models of Cancer Therapy Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Martín-Fernández G; Mouse Models of Cancer Therapy Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., González-Larreategui Í; Mouse Models of Cancer Therapy Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., López-Estévez S; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Brown-Swigart L; Department of Pathology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA., Beaulieu ME; Mouse Models of Cancer Therapy Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Whitfield JR; Mouse Models of Cancer Therapy Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Madan B; Program in Cancer and Stem Cell Biology, Duke-National University of Singapore (NUS) Medical School, Singapore, Singapore., Virshup DM; Program in Cancer and Stem Cell Biology, Duke-National University of Singapore (NUS) Medical School, Singapore, Singapore., Evan GI; Department of Biochemistry, University of Cambridge, Cambridge, UK., Soucek L; Mouse Models of Cancer Therapy Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain lsoucek@vhio.net.; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Publikováno v:
Life science alliance [Life Sci Alliance] 2021 Mar 02; Vol. 4 (5). Date of Electronic Publication: 2021 Mar 02 (Print Publication: 2021).
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy.
Autor:
Beaulieu ME; Peptomyc S.L., Edifici Cellex, Hospital Vall d'Hebron, Barcelona, 08035, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Edifici Cellex, Hospital Vall d'Hebron, Barcelona, 08035, Spain., Jauset T; Peptomyc S.L., Edifici Cellex, Hospital Vall d'Hebron, Barcelona, 08035, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Edifici Cellex, Hospital Vall d'Hebron, Barcelona, 08035, Spain., Massó-Vallés D; Peptomyc S.L., Edifici Cellex, Hospital Vall d'Hebron, Barcelona, 08035, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Edifici Cellex, Hospital Vall d'Hebron, Barcelona, 08035, Spain., Martínez-Martín S; Vall d'Hebron Institute of Oncology (VHIO), Edifici Cellex, Hospital Vall d'Hebron, Barcelona, 08035, Spain., Rahl P; Syros Pharmaceuticals, Cambridge, MA 02139, USA., Maltais L; Département de Biochimie, PROTÉO and Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec J1H 5N4, Canada., Zacarias-Fluck MF; Vall d'Hebron Institute of Oncology (VHIO), Edifici Cellex, Hospital Vall d'Hebron, Barcelona, 08035, Spain., Casacuberta-Serra S; Peptomyc S.L., Edifici Cellex, Hospital Vall d'Hebron, Barcelona, 08035, Spain.; Vall d'Hebron Institute of Oncology (VHIO), Edifici Cellex, Hospital Vall d'Hebron, Barcelona, 08035, Spain., Serrano Del Pozo E; Vall d'Hebron Institute of Oncology (VHIO), Edifici Cellex, Hospital Vall d'Hebron, Barcelona, 08035, Spain., Fiore C; Syros Pharmaceuticals, Cambridge, MA 02139, USA., Foradada L; Peptomyc S.L., Edifici Cellex, Hospital Vall d'Hebron, Barcelona, 08035, Spain., Cano VC; Vall d'Hebron Institute of Oncology (VHIO), Edifici Cellex, Hospital Vall d'Hebron, Barcelona, 08035, Spain., Sánchez-Hervás M; Vall d'Hebron Institute of Oncology (VHIO), Edifici Cellex, Hospital Vall d'Hebron, Barcelona, 08035, Spain., Guenther M; Syros Pharmaceuticals, Cambridge, MA 02139, USA., Romero Sanz E; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, 28040, Spain., Oteo M; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, 28040, Spain., Tremblay C; Département de Biochimie, PROTÉO and Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec J1H 5N4, Canada., Martín G; Vall d'Hebron Institute of Oncology (VHIO), Edifici Cellex, Hospital Vall d'Hebron, Barcelona, 08035, Spain., Letourneau D; Département de Biochimie, PROTÉO and Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec J1H 5N4, Canada., Montagne M; Département de Biochimie, PROTÉO and Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec J1H 5N4, Canada., Morcillo Alonso MÁ; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, 28040, Spain., Whitfield JR; Vall d'Hebron Institute of Oncology (VHIO), Edifici Cellex, Hospital Vall d'Hebron, Barcelona, 08035, Spain., Lavigne P; Département de Biochimie, PROTÉO and Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec J1H 5N4, Canada., Soucek L; Peptomyc S.L., Edifici Cellex, Hospital Vall d'Hebron, Barcelona, 08035, Spain. lsoucek@vhio.net.; Vall d'Hebron Institute of Oncology (VHIO), Edifici Cellex, Hospital Vall d'Hebron, Barcelona, 08035, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, 08010, Spain.; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Bellaterra, 08193 , Spain.
Publikováno v:
Science translational medicine [Sci Transl Med] 2019 Mar 20; Vol. 11 (484).